Ironwood Pharmaceuticals Announced Topline Results From Its Pivotal Phase 3 STARS Trial Of Once-weekly Subcutaneous Apraglutide In Reducing Parenteral Support Dependency In Adult Patients With Short Bowel Syndrome With Intestinal Failure

Author: Benzinga Newsdesk | February 29, 2024 07:17am

Apraglutide met the primary endpoint of relative change from baseline in actual weekly parenteral support (PS) volume at week 24, driven by both stoma and colon-in-continuity populations –

– Apraglutide also showed a clinically meaningful improvement at week 24, with patients achieving at least one day off PS per week –

– Apraglutide was generally well-tolerated, and the safety profile was consistent with previously-reported studies of apraglutide in this patient population –

– Ironwood to submit new drug application and other regulatory filings for apraglutide as a once-weekly GLP-2 analog for use in adult patients with SBS who are dependent on PS –

Posted In: IRWD